Drug Approval | June 10, 2022
Sanofi Dupixent gets USFDA nod for atopic dermatitis
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
The £118 million Mazumdar-Shaw Advanced Research Centre (ARC) will be the creative and collaborative heart of cross-disciplinary research at the University of Glasgow.
Marinus has broadened inclusion criteria in the RAISE trial to allow for enrollment of patients previously treated with IV anesthesia.
We have grown from $10 billion to $80 billion. India is not too far from reaching the league of top-10 countries in Biotech's global ecosystem”
Healthcare is timely and personal – and its delivery should be too
Bayer now present in four of the largest biotechnology hubs in the United States
A big boost to healthcare efforts of Ayush through NARIP, CCRAS
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
Based on a post hoc analysis, fewer required respiratory interventions
TLANDO was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.
Subscribe To Our Newsletter & Stay Updated
